Seeking Alpha

Life Sciences Report

View as an RSS Feed
Latest comments  |  Highest rated
  • Off To The Races With Extraordinary Biotech And Medtech Companies: Jason Napodano [View article]
    Jason Napodano spoke with the company and got back to us with a response regarding #2:

    "Parcopa is a levodopa and carbidopa combination the same as Sinemet. It is administered 3-4 times daily and is not apomorphine.

    Many, if not most, patients on levodopa (and its combinations) will eventually experience “off” episodes specifically because of the use of levodopa; because of its latency to “on” and rapid “off”. To manage these episodes which occur first thing in the morning and several times during the day, some neurologists prescribe apomorphine, the only approved drug to be used as a rescue therapy for acute “off” episodes. There are a number of clinical research papers published in leading journals by leading neurologist that confirm the benefit and use of apomorphine as an acute rescue therapy as well as confirm the existence of “Off” its severity and frequency.

    Many neurologists do not prescribe apomorphine. Some have clinical concerns with prescribing injectable apomorphine to Parkinson’s patients, but some are simply unaware of apomorphine. Once a convenient sublingual strip formulation is available, there will be an opportunity to educate neurologists about apomorphine and its place in therapy for Parkinson’s patients alongside levodopa and carbidopa combinations. While it is suggested that a more sustained and steady delivery of LD could reduce OFF time, the development of OFF episodes is directly related to the use of LD in the advancing Parkinson's patient. In the short term, newer LD preparations may help total OFF time but have no effect on the acute relief of OFF episodes like apomorphine does.

    The reason I like Cynapsus is that they are not re-inventing the wheel. Rescue from acute “off” episodes is a real clinical need that is currently poorly served by the only drug that can provide patients with almost immediate relief. APL 130277 is a sublingual thin film strip project, if successful, will be the only company in the last 15 years, of some dozen or so companies, to have solved the convenient and more tolerable delivery alternative to the sub q injection."
    Aug 7 01:08 PM | 1 Like Like |Link to Comment
  • Off To The Races With Extraordinary Biotech And Medtech Companies: Jason Napodano [View article]
    You're welcome, Kenneth. Thanks for the great question and thank you for reading.
    Aug 8 12:13 PM | Likes Like |Link to Comment
  • Off To The Races With Extraordinary Biotech And Medtech Companies: Jason Napodano [View article]
    Hi Kenneth - Yes, we often edit company mentions out of our articles due to SA's restrictions. You can find the full articles on our Instablog or on our website: http://bit.ly/16xtfh8.

    I will see if I can relay your question #2 to Mr. Napodano and will post his reply.
    Aug 6 01:20 PM | Likes Like |Link to Comment
  • Off To The Races With Extraordinary Biotech And Medtech Companies: Jason Napodano [View article]
    mickeyPS - we can try to get a hold of them for you. If you want to give us your info here: http://bit.ly/15B8dja
    Aug 5 04:37 PM | Likes Like |Link to Comment
  • Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential [View article]
    Thanks, Jolk. That is correct. We will update the article.
    May 6 05:30 PM | Likes Like |Link to Comment
  • Anything For A Buck: Jim Letourneau Looks To Canadian Biotech For Opportunity [View article]
    Good point, Cassandra. We will try to use tickers from reputable exchanges whenever possible going forward.
    Mar 26 06:11 PM | Likes Like |Link to Comment
  • The Life Sciences Report Watchlist 2013 [View instapost]
    We published an Editor's Note on our site, but it did not make it to the article as posted here on SA. Thanks for pointing this out, Suryan, the Editor's Note should appear on the article here soon.
    Feb 4 05:38 PM | Likes Like |Link to Comment
COMMENTS STATS
7 Comments
1 Like